European Commission Approves Roche Drug For Age-Related Macular Degeneration
The European Commission has approved Roche Holding AG's Susvimo for the treatment of neovascular age-related macular degeneration (AMD).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
European Commission approves Roche’s Susvimo® for nAMD treatment
Roche says the European Commission approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for neovascular age-related macular degeneration (nAMD).